Since first opening for business in 2002, employees at ScinoPharm Kunshan have developed processes for either the key intermediate or the final product of 15 APIs. Nine of the processes for intermediate synthesis have been used for the manufacture of key intermediates for use in GMP manufacture of APIs in ScinoPharm Taiwan. A similar number of API processes developed at ScinoPharm Kunshan have been used in the GMP manufacture of APIs in ScinoPharm Taiwan.

ScinoPharm generic APIs that SPK developed part, or all of the process:

• Cladribine (full API process) – and manufacture an intermediate for API production
• Bimatoprost (full API process) – also manufacture two intermediates for API production
• Travoprost (full API process) – also manufacture two intermediates for API production
• Decitabine (full API process) – also manufacture an intermediate for API production
• Azacitidine (full API process)
• Galantamine (key intermediate process) – manufacture an intermediate for API production
• Paclitaxel and Docetaxel (“side chain” process) – manufacture an intermediate for API production
• Fulvestrant (key intermediate process) –manufacture an intermediate for API production
• Zolpidem (full API process)
• Topiramate (full API process)
• Risperidone (full API process)
• Gemcitabine (full API process) – manufacture an intermediate for API production
• Tamsulosin (full API process)

Generic API's being developed at SPK in 2010:

• Clofarabine (full API process)
• Bortezomib (full API process)
• Lubiprostone (full API process)
• Lapatinib (full API process)
• Sunitinib (full API process)

Intermediates and ligands developed at SPK:

• 8-Benzyloxy-5-(2-bromoacetyl)-quinolin-2(1H)-one
• Sharpless's (DHQ)₂-PHAL chiral dihydroxylation ligand.
• Ethyl 2-(diphenylmethyleneamino)acetate (benzophenone ethyl glycinate imine)
• (R) - and (S)-1-(3-chlorophenoxy)-3-mercaptopropan-2-ol